# Cannapharmarx, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cannapharmarx, Inc.). ## Overview CannaPharmaRx, Inc. is a U.S.-listed company that has shifted from its earlier corporate history to focus on cannabis cultivation and medical cannabis product sales, primarily through operations in Canada. The company recommissioned a 55,000 square foot indoor facility in Cremona, Alberta, and now produces and sells medical cannabis and craft products. Its recent revenue growth has been driven by expanded product offerings, improved distribution, and new retail partner relationships. The business remains early-stage and capital constrained, with operations still scaling and significant dependence on financing and related-party support. ## Products & services • Medical cannabis cultivation and production • Craft cannabis product sales • Indoor grow facility operations in Alberta • Wholesale cannabis sales to retail and related-party buyers • Product development and facility recommissioning - **Medical cannabis products** (85%) — Cultivated cannabis flower and related medical-use products sold into domestic and export channels. - **Craft cannabis products** (10%) — Higher-specification batches marketed at premium pricing based on potency and quality. - **Wholesale distribution** (5%) — Bulk product sales to retail partners and related-party distributors that move inventory into end markets. - Medical cannabis cultivation and production - Craft cannabis product sales - Indoor grow facility operations in Alberta - Wholesale cannabis sales to retail and related-party buyers - Product development and facility recommissioning ## Customers The company sells cannabis products to retail partners and distributors that place product into medical cannabis channels. Its disclosures also show sales to a related-party Israeli buyer, indicating that export or cross-border commercial relationships are part of the current go-to-market model. Pricing varies by market and batch quality, with premium and medium batches sold at different gram prices across Germany, Israel, Canada, and Portugal. Customer demand is tied to product potency, regulatory acceptance, and the company’s ability to maintain consistent supply and distribution access. - **Retail cannabis partners** (primary) — Retail partners buy medical cannabis inventory for resale, helping the company expand market penetration and distribution reach. - **International distributors** (secondary) — Distributors in markets such as Israel and Europe buy batches for local medical cannabis channels and market development. - **Related-party commercial buyers** (secondary) — Affiliated buyers have purchased product and appear to support early commercialization and market access. - **Premium batch buyers** (secondary) — Customers seeking higher-THC, higher-priced batches buy for quality and potency differentiation. - Medical cannabis retailers buying product for resale to end consumers - International distributors and partners sourcing batches for local markets - Related-party buyers in Israel used to expand market presence - Customers seeking higher-THC premium batches and lower-priced medium batches - Buyers that value reliable supply, regulatory compliance, and potency ## Geography Operationally, the company is centered in Alberta, Canada, where it runs its indoor cultivation facility and maintains its principal executive office in Calgary. The Cremona facility is the core production asset and is being ramped up in phases, which makes Canada the key operating geography. Commercially, the company references sales and pricing in Germany, Israel, Canada, and Portugal, suggesting an export-oriented or internationally distributed sales footprint. Because the business depends on cannabis licensing and product standards, geography matters both for regulatory access and for the ability to place product into higher-value markets. - Canada is the operating base and main production location - Cremona, Alberta facility is the core cultivation asset - Calgary, Alberta is the principal executive office - Sales references include Germany, Israel, Canada, and Portugal - International market access affects pricing and commercialization ## Strategy The company’s strategy is to scale its indoor cannabis farm, increase utilization of the Cremona facility, and expand production capacity over the next one to two years. Management is also focused on improving distribution capabilities and adding retail partners to support revenue growth. A further strategic priority is market development outside Canada, including Israel and other international markets where the company has already referenced pricing and sales relationships. Because the company is capital constrained, financing and related-party support are also central to executing the operating plan. - **Increase facility utilization** (medium-term) — Higher utilization should spread fixed cultivation costs over more output and improve commercial scale. - **Expand distribution and retail partnerships** (short-term) — Broader channel access is needed to convert production into recurring sales and reduce reliance on a small set of buyers. - **Secure financing and liquidity** (short-term) — The company needs external capital to fund operations, working capital, and expansion while it remains cash constrained. - Ramp up the Cremona facility from partial to fuller utilization - Expand production capacity by opening additional drying/packing capacity - Grow medical cannabis sales through new retail partners - Improve distribution capabilities to widen market reach - Develop international market access, including Israel and Europe - Raise additional capital to fund operations and expansion ## Risks The most immediate risk is going concern and liquidity risk, as the company reports minimal cash, a large working capital deficiency, and dependence on new financing to continue operations. Cannabis cultivation also carries operational risk because yields, potency, and product quality directly affect sellability and pricing, and the company has already recorded significant inventory impairment from market price compression and sub-threshold THC levels. Regulatory risk is material because cannabis production and sales depend on licenses, compliance with changing standards, and market access in each jurisdiction. The business is also exposed to concentration and related-party risk because financing, leases, and some sales involve affiliated parties, which can limit flexibility and create governance concerns. - **Going concern and liquidity shortfall** [critical] — The company states it lacks adequate working capital and depends on raising additional capital to meet obligations and continue operations. - **Inventory impairment and price compression** [high] — Management recorded large inventory write-downs because market prices fell and some inventory failed potency thresholds or became less marketable. - **Cannabis regulatory and licensing risk** [high] — Cultivation and sales depend on Health Canada and other jurisdiction-specific standards that can change product recoverability and market access. - **Related-party dependence** [medium] — Sales, leases, loans, and security arrangements involve affiliates and insiders, increasing dependence on non-arm's-length support. - Going concern risk due to severe liquidity shortfall and negative working capital - Inventory impairment risk from price compression and product specification changes - Cannabis regulatory risk across production, potency, and market access rules - Customer concentration and related-party dependence in early commercialization - Operational risk from cultivation yields, THC potency, and facility ramp-up - Financing risk because growth depends on equity, debt, or partner capital ## Accounting Revenue is recognized on cannabis product sales, and quarterly results can be volatile because sales volumes have only recently begun to ramp. Cost of goods sold is unusually important because it includes direct production costs as well as large inventory impairment charges, which have materially affected gross loss. Inventory valuation is a critical judgment area: management must estimate net realizable value and assess whether THC potency, aging, and regulatory changes reduce recoverability. Lease accounting and related-party arrangements also matter because the company has significant facility obligations, unpaid lease amounts, and security/royalty agreements that can affect both expenses and liabilities. - **Inventory impairment and net realizable value** — Directly reduces gross margin and can signal product quality or demand issues - **Revenue recognition on cannabis sales** — Creates volatility in reported revenue and comparability across quarters - **Related-party lease and royalty arrangements** — Can materially affect cost of goods sold, liabilities, and financing disclosures - **Going concern assessment** — Affects investor assessment of asset recoverability and financing assumptions - Revenue timing depends on product sales and can swing sharply quarter to quarter - Inventory valuation drives gross loss because impairment charges are large - Net realizable value estimates are sensitive to price compression and potency thresholds - Lease and rent obligations affect cost of goods sold and financing-related expense - Related-party agreements can create unusual liabilities, royalties, and security interests - Going concern disclosures affect how investors interpret the financial statements --- *Last updated: 2026-08-11T04:46:25.362432+00:00*